A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma

This phase 1/2 study in patients with newly diagnosed multiple myeloma (N = 53) assessed CRd—carfilzomib (20, 27, or 36 mg/m(2), days 1, 2, 8, 9, 15, 16 and 1, 2, 15, 16 after cycle 8), lenalidomide (25 mg/d, days 1-21), and weekly dexamethasone (40/20 mg cycles 1-4/5+)—in 28-day cycles. After cycle...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Blood
Prif Awduron: Jakubowiak, Andrzej J., Dytfeld, Dominik, Griffith, Kent A., Lebovic, Daniel, Vesole, David H., Jagannath, Sundar, Al-Zoubi, Ammar, Anderson, Tara, Nordgren, Brian, Detweiler-Short, Kristen, Stockerl-Goldstein, Keith, Ahmed, Asra, Jobkar, Terri, Durecki, Diane E., McDonnell, Kathryn, Mietzel, Melissa, Couriel, Daniel, Kaminski, Mark, Vij, Ravi
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Hematology 2012
Pynciau:
Clinical Trials and Observations
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5162553/
https://ncbi.nlm.nih.gov/pubmed/22665938
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-04-422683
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg